SECOND AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • October 20th, 2021 • Allarity Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledOctober 20th, 2021 Company IndustryThis Second Amendment to the Exclusive License Agreement (“Second Amendment”) effective as of August 3, 2021 (“Second Amendment Effective Date”) is by and between: EISAI INC., with its principal office at 100 Tice Blvd., Woodcliff Lake, NJ 07093, United States of America (“Eisai”) and ALLARITY THERAPEUTICS A/S, with its principal office at Venlighedsvej 1, DK-2970 Hoersholm, Denmark (“Allarity”) (formerly known as Oncology Venture ApS), with reference to the following:
FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • October 20th, 2021 • Allarity Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledOctober 20th, 2021 Company IndustryThis First Amendment (“First Amendment”) to Exclusive License Agreement effective as of Dec,. 11 2020 (“First Amendment Effective Date”) is by and between: EISAI INC., with its principal office at 100 Tice Blvd., Woodcliff Lake, NJ 07093, United States of America (“Eisai”) and ALLARITY THERAPEUTICS A/S, with its principal office at Venlighedsvej I, DK-2970 Hoersholm, Denmark (“Allarity”)(formerly Oncology Venture A/S), with reference to the following:
THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • October 20th, 2021 • Allarity Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledOctober 20th, 2021 Company IndustryThis Third Amendment (“Third Amendment”) to Exclusive License Agreement effective as of September 28, 2021 (“Third Amendment Effective Date”) is by and between: SMERUD MEDICAL RESEARCH INTERNATIONAL AS, a company organized and existing under the laws of Norway, with a principal place of business is located at Thunes vei 2, N-0274 Oslo, Norway (“Smerud”) and ALLARITY THERAPEUTICS A/S, a company organized and existing under the laws of Denmark, with a principal place of business at Venlighedsvej 1, DK-2970 Hoersholm, Denmark (“Allarity”)(formerly Oncology Venture A/S), with reference to the following:
LICENSE AGREEMENT between NOVARTIS PHARMA AG and ONCOLOGY VENTURE ApSLicense Agreement • October 20th, 2021 • Allarity Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledOctober 20th, 2021 Company Industry JurisdictionThis LICENSE AGREEMENT (“License Agreement”) is made as of the 6. day of April, 2018 (“Effective Date”), by and between Novartis Pharma AG, a company organized under the laws of Switzerland and located at Lichtstrasse 35, 4056 Basel, Switzerland (“Novartis”), and Oncology Venture ApS, a company organized under the laws of Denmark, with headquarters at Venlighedsvej 1, DK-2970 Hoersholm, Denmark (“OV”). Novartis and OV are each referred to individually as a “Party” and together as the “Parties.”